Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGB + Massed PE for PTSD
NCT04302181Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropivacaine in post-traumatic stress disorder (PTSD), sponsored by UT Health San Antonio. Primary endpoints: Clinician-Administered PTSD Scale at 3 months and Posttraumatic Stress Disorder Checklist at 3 months. Started Oct 2020; status: completed.
02
Drugs
ropivacaine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04302181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04302181.